Immune-mediated inflammation across disease boundaries: breaking down research silos

If new treatments for immune-mediated inflammatory diseases (IMIDs) are to emerge, then a radical new approach that moves the field from one that is based on clinical signs and symptoms to one that is based on immunological and molecular mechanisms is urgently needed. This requires a new way of thinking: that IMIDs should be approached as having shared common pathogenic cells and pathways, and that therapies should be targeted at these cells and processes rather than clinical features.